IR@PKUHSC  > 北京大学第九临床医学院
学科主题临床医学
Targeting bladder cancer using activated T cells armed with bispecific antibodies
Ma, Juan1,2,3; Ge, Jing1,2,3; Xue, Xin4; Xiu, Weigang1,3,5,6; Ma, Pan7; Sun, Ximing1,2,3; Zhang, Man1,2,3
通讯作者Ma, Juan(1,2,3) ; Zhang, Man(1,2,3)
关键词bladder cancer EGFR HER2 immunotherapy activated T cells
刊名ONCOLOGY REPORTS
2018-03-01
DOI10.3892/or.2018.6211
39期:3页:1245-1252
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Oncology
研究领域[WOS]Oncology
关键词[WOS]ADVANCED UROTHELIAL CARCINOMA ; PHASE-II TRIAL ; RANDOMIZED-TRIAL ; BREAST-CANCER ; IN-VITRO ; THERAPY ; GEMCITABINE ; HER2 ; MULTICENTER ; RESISTANCE
英文摘要

In the present study, we aimed to investigate whether EGFR or HER2 may serve as a target for T cell-mediated immunotherapy against human bladder cancer. Expression of EGFR and HER2 was detected on the surface of bladder cancer cells, including Pumc-91 and T24 cells, and their chemotherapeutic drug-resistant counterparts. Activated T cells (ATCs) were generated from healthy PBMCs that were stimulated by the combination of anti-CD3 monoclonal antibody and anti-CD28 monoclonal antibody in the presence of interleukin-2 for 14 days. The ATCs were then armed with chemically hetero-conjugated anti-CD3xanti-EGFR (EGFRBi-Ab) or anti-CD3xanti-HER2 (HER2Bi-Ab). The specific cytolytic activity of ATCs armed with EGFRBi-Ab or HER2Bi-Ab against human bladder cancer cells was evaluated by lactate dehydrogenase activity assays in vitro. In contrast to unarmed ATCs, EGFRBi-Ab-armed ATCs and HER2Bi-Ab-armed ATCs showed increased cytotoxic activity against bladder cancer cells. Moreover, Bi-Ab-armed ATCs expressed higher levels of activating marker CD69 and secreted more IFN-gamma, TNF-alpha and IL-2 than did unarmed ATCs. EGFRBi-Ab- or HER2Bi-Ab-armed ATCs may provide a promising immunotherapy for bladder cancer.

语种英语
WOS记录号WOS:000424401500040
通讯作者邮箱majuan96@sina.com ; zhangman@bjsjth.cn
ISSN1021-335X
引用统计
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/140376
专题北京大学第九临床医学院
北京大学口腔医学院_人事处
作者单位1.Peking Univ, Sch Clin Med 9, Beijing, Peoples R China;
2.Capital Med Univ, Beijing Shijitan Hosp, Clin Lab Med, 10 Tieyi Rd, Beijing 100038, Peoples R China;
3.Beijing Key Lab Urinary Cellular Mol Diagnost, Beijing 100038, Peoples R China;
4.Acad Chinese Med Sci, China Basic Med Theory Chinese Med, Dept Immunol, Beijing 100700, Peoples R China;
5.Sichuan Univ, West China Hosp, Dept Thorac Oncol, Ctr Canc, Chengdu 610041, Sichuan, Peoples R China;
6.Sichuan Univ, West China Hosp, State Key Lab Biotherapy, Chengdu 610041, Sichuan, Peoples R China;
7.Chinese Acad Sci, Inst Biophys, Key Lab Prot & Peptide Pharmaceut, Beijing 100101, Peoples R China
推荐引用方式
GB/T 7714
Ma, Juan,Ge, Jing,Xue, Xin,et al. Targeting bladder cancer using activated T cells armed with bispecific antibodies[J]. ONCOLOGY REPORTS,2018,39(3):1245-1252.
APA Ma, Juan.,Ge, Jing.,Xue, Xin.,Xiu, Weigang.,Ma, Pan.,...&Zhang, Man.(2018).Targeting bladder cancer using activated T cells armed with bispecific antibodies.ONCOLOGY REPORTS,39(3),1245-1252.
MLA Ma, Juan,et al."Targeting bladder cancer using activated T cells armed with bispecific antibodies".ONCOLOGY REPORTS 39.3(2018):1245-1252.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Ma, Juan]的文章
[Ge, Jing]的文章
[Xue, Xin]的文章
百度学术
百度学术中相似的文章
[Ma, Juan]的文章
[Ge, Jing]的文章
[Xue, Xin]的文章
必应学术
必应学术中相似的文章
[Ma, Juan]的文章
[Ge, Jing]的文章
[Xue, Xin]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。